Evidence map›Paper›PMID 24552251›Full record

ArticleNano letters2014

Particle replication in nonwetting templates nanoparticles with tumor selective alkyl silyl ether docetaxel prodrug reduces toxicity.

Kevin S Chu, Mathew C Finniss, Allison N Schorzman, Jennifer L Kuijer, J Christopher Luft, Charles J Bowerman, Mary E Napier, Zishan A Haroon, William C Zamboni, Joseph M DeSimone

Abstract read
In one paragraph

Article in Nano letters, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
3.4field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 45 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Biomimetic particles as therapeutics.Trends in biotechnology · 2015
    Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Shaping the future of nanomedicine: anisotropy in polymeric nanoparticle design.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Kevin S ChuDepartment of Pharmaceutical Sciences, ‡Department of Chemistry, §Lineberger Comprehensive Cancer Center, ∥Department of Biochemistry and Biophysics, ⊥Institute for Pharmacogenomics and Individualized Therapy, ¶Carolina Center of Cancer Nanotechnology Excellence, □Department of Pharmacology, Eshelman School of Pharmacy, ■Institute for Nanomedicine, ○Institute for Advanced Materials, University of North Carolina at Chapel Hill , Chapel Hill, North Carolina 27599, United States.
Mathew C Finniss
Allison N Schorzman
Jennifer L Kuijer
J Christopher Luft
Charles J Bowerman
Mary E Napier
Zishan A Haroon
William C Zamboni
Joseph M DeSimone
North Carolina State University · US

Funding

"Smart" Nanoparticles for Cancer Therapy and ImagingU54CA119343 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI JULIANO, RUDOLPH · 2005 to 2009
$18.3M
Translational Nanosystems for Improved Lung Cancer Treatment with Small MoleculesU54CA151652 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DESIMONE, JOSEPH M. · 2010 to 2014
$12.1M
NCI NIH HHS U54 CA119343NCI NIH HHS U54-CA119343NCI NIH HHS U54 CA151652NCI NIH HHS U54-CA151652
6 · The paper itself

Abstract

Delivery systems designed to have triggered release after passively targeting the tumor may improve small molecule chemotherapeutic delivery. Particle replication in nonwetting templates was used to prepare nanoparticles to passively target solid tumors in an A549 subcutaneous xenograft model. An acid labile prodrug was delivered to minimize systemic free docetaxel concentrations and improve tolerability without compromising efficacy.

Indexed as

Drug CarriersProdrugsTaxoidsAnimalsDocetaxelHumansMiceNanoparticlesNeoplasmsWettabilityXenograft Model Antitumor AssaysDocetaxelDrug CarriersProdrugsTaxoids

Identifiers

PMID24552251
PMCPMC4157645
OpenAlexW2159706546

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.